Join our daily newsletter At The Bell to receive exclusive market insights
- CardieX (CDX) and its manufacturing partner, Andon, submit its blood pressure and arterial health monitor, CONNEQT Pulse, to the US Food and Drug Administration (FDA)
- Subject to FDA clearance, Pulse will be the first arterial health monitor for CardieX
- The product will allow clinicians, patients and consumers alike to gain more advanced insights into cardiovascular health
- CardieX CEO Craig Cooper says this application is the “most significant event for CardieX in over 20 years”
- CDX shares jump 20.7 per cent to 35 cents each at 12:38 pm AEST
CardieX (CDX) and its manufacturing partner, Andon, have submitted CONNEQT Pulse to the US Food and Drug Administration (FDA).
Pulse is a dual blood pressure and arterial health monitor that is targeted for the home health, remote patient monitoring and decentralised clinical trial markets.
Subject to FDA clearance, Pulse will be the first arterial health monitor for CardieX and according to the company, will be the first blood pressure monitor to incorporate “over the air” customisable display screens.
Pulse will allow clinicians, patients and consumers alike to gain more advanced insights
into cardiovascular health.
CardieX CEO Craig Cooper said this application is the “most significant event for CardieX in over 20 years” when the company’s SphygmoCor was FDA cleared.
“Pulse extends that legacy into new, significant markets and importantly, is set to
redefine the diagnostic paradigm for the identification and treatment of vascular and
arterial disease,” he said.
Pulse is built upon CardieX’s existing SphygmoCor central blood pressure technology which is developed by CardieX’s subsidiary, ATCOR.
CDX shares have jumped 20.7 per cent to 35 cents each at 12:38 pm AEST.
